Lung cancer (Amsterdam, Netherlands)
Journal
Overview
publication venue for
-
Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib..
178.
2023
-
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib..
166.
2021
-
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancers..
162.
2021
-
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer..
161.
2021
-
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions..
159.
2021
-
Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study..
160.
2021
-
Everolimus in the treatment of metastatic thymic epithelial tumors..
149.
2020
-
Downregulation of CYLD promotes IFN-γ mediated PD-L1 expression in thymic epithelial tumors..
147.
2020
-
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study..
145.
2020
-
Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer..
145.
2020
-
Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study..
142.
2020
-
Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity..
139.
2019
-
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer..
136.
2019
-
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer..
134.
2019
-
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis..
133.
2019
-
Outcomes of Stage III NSCLC with occult primary vs. known primary lesions..
127.
2018
-
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer..
122.
2018
-
Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients..
119.
2018
-
What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?.
118.
2018
-
High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer..
116.
2017
-
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib..
113.
2017
-
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers..
112.
2017
-
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas..
108.
2017
-
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib..
108.
2017
-
Investigation of patterns of nodal metastases in BRAF mutant lung cancer..
108.
2017
-
Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics..
106.
2017
-
Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib..
104.
2016
-
Expression of mesothelin in thymic carcinoma and its potential therapeutic significance..
101.
2016
-
Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers..
99.
2016
-
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer..
99.
2016
-
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?.
90.
2015
-
Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma..
89.
2015
-
Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements?.
86.
2014
-
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase..
86.
2014
-
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines..
85.
2014
-
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma..
84.
2014
-
Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China..
84.
2014
-
High expression of SNIP1 correlates with poor prognosis in non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro..
82.
2013
-
History of lung disease and risk of lung cancer in a population with high household fuel combustion exposures in rural China..
81.
2013
-
Reproducibility of the WHO classification of thymomas: practical implications..
79.
2012
-
Beliefs and attitudes about lung cancer screening among smokers..
77.
2012
-
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer..
77.
2012
-
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer..
76.
2011
-
Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas..
75.
2011
-
Safety and feasibility of a combined exercise intervention for inoperable lung cancer patients undergoing chemotherapy: a pilot study..
75.
2011
-
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis..
74.
2011
-
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer..
74.
2011
-
Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma..
74.
2011
-
Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study..
72.
2010
-
Health-related quality of life among early-stage, non-small cell, lung cancer survivors..
71.
2010
-
Variation in vascular distribution in small lung cancers..
68.
2009
-
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells..
68.
2009
-
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer..
67.
2009
-
Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications..
64.
2008
-
Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study..
62.
2008
-
Dietary factors, food contamination and lung cancer risk in Xuanwei, China..
61.
2008
-
Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer..
60.
2007
-
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells..
59.
2007
-
Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening..
56.
2007
-
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer..
55.
2006
-
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy..
55.
2006
-
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma..
54.
2006
-
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer..
52.
2006
-
A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer..
52.
2006
-
A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)..
50.
2005
-
Reduction of organ motion in lung tumors with respiratory gating..
51.
2005
-
The effect of smoking status on survival following radiation therapy for non-small cell lung cancer..
44.
2004
-
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma..
43.
2004
-
Expression of cancer/testis (CT) antigens in lung cancer..
42.
2003
-
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer..
39.
2003
-
Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine..
39.
2003
-
A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis..
38.
2002
-
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study..
38.
2002
-
Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling..
33.
2001
-
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer..
32.
2001
-
Early lung cancer action project pathology protocol..
39.
2003
-
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
1996
-
Introduction..
50S2.
2005
-
New approaches in the treatment of non-small cell lung cancer: taxanes in the treatment of NSCLC: pathways to progress..
38 Suppl 4.
2002
-
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
2019
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)